Jeffrey A. Barnes

2.5k total citations
59 papers, 1.3k citations indexed

About

Jeffrey A. Barnes is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jeffrey A. Barnes has authored 59 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pathology and Forensic Medicine, 24 papers in Oncology and 15 papers in Genetics. Recurrent topics in Jeffrey A. Barnes's work include Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CNS Lymphoma Diagnosis and Treatment (14 papers). Jeffrey A. Barnes is often cited by papers focused on Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CNS Lymphoma Diagnosis and Treatment (14 papers). Jeffrey A. Barnes collaborates with scholars based in United States, Germany and France. Jeffrey A. Barnes's co-authors include Jeremy S. Abramson, Ephraim P. Hochberg, Christiana E. Toomey, Donna Neuberg, Shelley A. Tischkau, Martha U. Gillette, Jessica W. Barnes, Ann S. LaCasce, Jennifer W. Mitchell and Yang Feng and has published in prestigious journals such as Science, New England Journal of Medicine and Neuron.

In The Last Decade

Jeffrey A. Barnes

57 papers receiving 1.3k citations

Peers

Countries citing papers authored by Jeffrey A. Barnes

Since Specialization

Citations

This map shows the geographic impact of Jeffrey A. Barnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Barnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Barnes more than expected).

Fields of papers citing papers by Jeffrey A. Barnes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Barnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Barnes. The network helps show where Jeffrey A. Barnes may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Barnes

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Barnes. A scholar is included among the top collaborators of Jeffrey A. Barnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Barnes. Jeffrey A. Barnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy 2025 ·Journal of the National Comprehensive Cancer Network ·P. Connor Johnson, Jeremy S. Abramson, Ann S. LaCasce, Philippe Armand, Jeffrey A. Barnes, Reid W. Merryman, Jacob D. Soumerai, Ephraim P. Hochberg, Ronald W. Takvorian, Caron A. Jacobson, Jennifer L. Crombie, David C. Fisher, Joel Schwartz, Robb S. Friedman, (unknown), (unknown), (unknown), Norman Markowitz, Oreofe O. Odejide, Areej El‐Jawahri	1
2	Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone ( BV ‐ CHEP ) for the treatment of aggressive adult T‐cell leukaemia/lymphoma 2025 ·British Journal of Haematology ·Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval‐Sus, Natalie S. Grover, Anne Beaven, (unknown), Anthony C Shelton, Xianming Tan, (unknown), Areej El‐Jawahri, Shayna Sarosiek, J. Mark Sloan	1
3	Secondary Cancer Risk Among Patients With Primary Cutaneous B-cell Lymphoma 2025 ·JAMA Dermatology ·(unknown), Sara Behbahani, Jeffrey A. Barnes, (unknown), (unknown)	0
4	A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas 2025 ·Leukemia & lymphoma ·Mwanasha H. Merrill, Robert Redd, David C. Fisher, Jeremy S. Abramson, Jeffrey A. Barnes, Jaehyuk Choi, Caron A. Jacobson, Austin I. Kim, Matthew A. Lunning, (unknown), (unknown), (unknown), Philippe Armand, (unknown)	1
5	5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)—Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma 2025 ·International Journal of Radiation OncologyBiologyPhysics ·Hazim Ababneh, Andrea K. Ng, Juefeng Wan, (unknown), Lin Zhu, (unknown), P. Connor Johnson, (unknown), Jonathan E. Leeman, Jacob D. Soumerai, Jeremy S. Abramson, Jeffrey A. Barnes, Ronald W. Takvorian, Matthew J. Frigault, J. Pursley, Chirayu G. Patel	3
6	Prevalence of autoimmune diseases in cutaneous B-cell lymphoma: A retrospective cross sectional analysis 2023 ·Journal of the American Academy of Dermatology ·(unknown), (unknown), (unknown), (unknown), Jeffrey A. Barnes, Chirayu G. Patel, Salvia Jain, Steven T. Chen	0
7	Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma 2023 ·Blood Advances ·Reem Karmali, Jeremy S. Abramson, Deborah M. Stephens, Jeffrey A. Barnes, Jane N. Winter, Shuo Ma, Juehua Gao, Jason Kaplan, Adam M. Petrich, Ephraim P. Hochberg, Tak Takvorian, Xinlei Mi, Valerie Nelson, Leo I. Gordon, Barbara Pro	3
8	Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma 2023 ·Blood ·Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval‐Sus, Natalie S. Grover, Anne Beaven, Xianming Tan, Areej El‐Jawahri, Shayna Sarosiek, J. Mark Sloan	1
9	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells 2019 ·Blood ·Philipp Karschnia, Justin T. Jordan, Deborah Forst, Isabel Arrillaga‐Romany, Tracy T. Batchelor, Joachim M. Baehring, Nathan F. Clement, L. Nicolas Gonzalez Castro, Aline Herlopian, Marcela V. Maus, (unknown), Jacob D. Soumerai, Ronald W. Takvorian, Ephraim P. Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Matthew J. Frigault, Jörg Dietrich	224
10	Primary cutaneous B-cell lymphomas— clinical and histopathologic features, differential diagnosis, and treatment 2018 ·Seminars in Cutaneous Medicine and Surgery ·Steven T. Chen, Jeffrey A. Barnes, Lyn M. Duncan	10
11	Case 19-2016 2016 ·New England Journal of Medicine ·(unknown), Joi B. Carter, Jeffrey A. Barnes, Rosalynn M. Nazarian	2
12	Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients 2016 ·Abdominal Radiology ·(unknown), Ciprian Catana, Jeremy S. Abramson, Grae Arabasz, (unknown), Onofrio A. Catalano, Victorine V. Muse, Michael A. Blake, Jeffrey A. Barnes, Martin J. Shelly, Ephraim P. Hochberg, Bruce R. Rosen, Alexander R. Guimarães	36
13	Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma 2015 ·Biology of Blood and Marrow Transplantation ·Yi‐Bin Chen, Shuli Li, David C. Fisher, (unknown), Candice Del Rio, Jeremy S. Abramson, Philippe Armand, Jeffrey A. Barnes, Jennifer R. Brown, Corey Cutler, Areej El‐Jawahri, Vincent T. Ho, Ephraim P. Hochberg, Steven L. McAfee, Ronald W. Takvorian, Thomas R. Spitzer, Joseph H. Antin, Robert J. Soiffer, Eric D. Jacobsen	13
14	Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study 2013 ·Leukemia & lymphoma ·Jeremy S. Abramson, Ronald W. Takvorian, David C. Fisher, Yang Feng, Eric D. Jacobsen, Jennifer R. Brown, Jeffrey A. Barnes, Donna Neuberg, Ephraim P. Hochberg	10
15	Case 24-2013 2013 ·New England Journal of Medicine ·Joi B. Carter, Jeffrey A. Barnes, Bethany L. Niell, Valentina Nardi	3
16	Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis 2011 ·Annals of Oncology ·Jeffrey A. Barnes, Ann S. LaCasce, Yang Feng, Christiana E. Toomey, Donna Neuberg, James Michaelson, Ephraim P. Hochberg, Jeremy S. Abramson	105
17	End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma 2010 ·Annals of Oncology ·Jeffrey A. Barnes, Ann S. LaCasce, Katherine Zukotynski, David Israel, Yang Feng, Donna Neuberg, Christiana E. Toomey, Ephraim P. Hochberg, George P. Canellos, Jeremy S. Abramson	72
18	Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma 2010 ·Cancer ·Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg	166
19	Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older 2010 ·Blood ·Christiana E. Toomey, (unknown), Alfred Ian Lee, Jeffrey A. Barnes, James Michaelson, Jeremy S. Abramson, Ephraim P. Hochberg	2
20	Protein Kinase G Type II Is Required for Night-to-Day Progression of the Mammalian Circadian Clock 2004 ·Neuron ·Shelley A. Tischkau, Jennifer W. Mitchell, Laura Pace, Jessica W. Barnes, Jeffrey A. Barnes, Martha U. Gillette	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact